Delayed elevation of international normalized ratio with concurrent clarithromycin and warfarin therapy

Pharmacotherapy

Volumn 18, Issue 2 I, 1998, Pages 386-391

  Oberg, Kristin C ^a,b  

^a NORTHEASTERN UNIVERSITY   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFUROXIME; CLARITHROMYCIN; CYTOCHROME P450; ERYTHROMYCIN; OFLOXACIN; PHYTOMENADIONE; WARFARIN;

ADULT; AGED; ANTICOAGULATION; ARTICLE; CASE REPORT; DRUG METABOLISM; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NORMAL VALUE; ORAL DRUG ADMINISTRATION; PNEUMONIA; PROTHROMBIN TIME;

AGED; ANTI-BACTERIAL AGENTS; ANTICOAGULANTS; BLOOD COAGULATION; CLARITHROMYCIN; DRUG INTERACTIONS; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; PROTHROMBIN TIME; WARFARIN;

EID: 0031919507     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Abbott Laboratories. Biaxin (clarithromycin) package insert. Abbott Park, IL; 1996.
2. Bartle WR. Possible warfarin-erythromycin interaction. Arch Intern Med 1980;140:985-7.
3. Schwartz J, Bachmann K, Perrigo E. Interaction between warfarin and erythromycin. South Med J 1983;76:91-3.
4. Sato RI, Gray DR, Brown SE. Warfarin interaction with erythromycin. Arch Intern Med 1984;144:2413-14.
5. Hassell D, Utt JK. Suspected interaction: warfarin and erythromycin. South Med J 1985;78:1015-16.
6. Watkins PB. Drug metabolism by cytochrome P450 in the liver and small bowel. Gastroenterol Clin North Am 1992;21: 511-26.
7. von Moltke LL, Greenblatt DJ, Schmider J, Harmatz JS, Shader RI. Metabolism of drugs by cytochrome P450 3A isoforms. Clin Pharmacokinet 1995;29:33-44.
8. Flockhart DA. Drug interactions and the cytochrome P450 system. Clin Pharmacokinet 1995;29:45-52.
9. Slaughter RL, Edwards DJ. Recent advances: the cytochrome P450 enzymes. Ann Pharmacother 1995;29:619-24.
10. Sanchez B, Muruzabal MJ, Peralta G, et al. Clarithromycin-oral anticoagulants interaction: report of five cases. Clin Drug Invest 1997;13:220-2.
11. Well PS, Holbrook AM, Crowther NR, Hirsch J. Interactions of warfarin with drugs and food. Ann Intern Med 1994;121: 676-83.
12. Bachmann K, Schwartz JI, Forney R, Frogameni A, Jauregui LE. The effect of erythromycin on the disposition kinetics of warfarin. Pharmacology 1984;28:171-6.
13. Periti P, Mazzei R, Mini E, Novelli A. Pharmacokinetic drug interactions of macrolides. Clin Pharmacokinet 1992;23: 106-31.
14. Kapusnik-Uner JE, Sande MA, Chambers HF. The pharmacological basis of therapeutics. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG, eds. Tetracyclines, chloramphenicol, erythromycin, and miscellaneous antibacterial agents. New York: McGraw-Hill, 1996:1123-53.
15. Hirsch J, Fuster V. Guide to anticoagulant therapy. 2. Oral anticoagulants. Circulation 1994;89:1469-80.
16. Lewis RJ, Trager WF. Warfarin metabolism in man: identification of metabolites in urine. J Clin Invest 1970; 49:907-13.
17. Lewis RJ, Trager WF. The metabolic fate of warfarin: studies on the metabolites in plasma. Ann NY Acad Sci 1971;179:205-12.
18. Goldstein JA, de Morais SMF. Biochemistry and molecular biology of the human CYP 2C subfamily. Pharmacogenetics 1994;4:285-99.
19. Rettie AE, Korzekwa KR, Kunze KL, et al. Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role of P-450 2C9 in the etiology of (S)-warfarin-drug interactions. Chem Res Toxicol 1992;5:54-9.
20. Goldstein JA, de Morasi SMF. Biochemistry and molecular biology of the human CYP 2C subfamily. Pharmacogenetics 1994;4:265-99.
21. Chan KK, Lewis RJ, Trager WF. Absolute configuration of the four warfarin alcohols. J Med Chem 1972;15:1265-70.
22. Hermans JJR, Thijssen JJW. Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics. Br J Pharmacol 1993;110:482-90.
23. Lewis RJ, Trager WF, Robinson AJ, Chan KK. Warfarin metabolite: the anticoagulation activity and pharmacology of warfarin alcohols. J Lab Clin Med 1973;81:925-31.
24. Almira M. Basic and clinical pharmacology. In: Katzung BG, ed. Drug biotransformation. Norwalk, CT: Appleton & Lange;1992:49-59.
25. Watkins PB. Role of cytochrome P450 in drug metabolism and hepatotoxicity. Semin Liver Dis 1990;10:235-50.
26. Benet LZ, Oie S, Schwartz JB. The pharmacological basis of therapeutics. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG, eds. Design and optimization of dosage regimens: pharmacokinetic data. New York: McGraw-Hill, 1996:1702-92.
27. Roden DM. Pharmacokinetics of amiodarone: implications for drug therapy. Am J Cardiol 1993;72:45-50F.
28. Gill J, Heel RC, Fitton A. Amiodarone. An overview of its pharmacologic properties, and review of its therapeutic use in cardiac arrhythmias. Drugs 1992;43:69-110.
29. Wah AH, Stephens MR, Buss DC, Routledge PA. Amiodarone reduces plasma warfarin clearance in man. Br J Clin Pharmacol 1985;20:707-9.
30. O'Reilly RA, Trager WF, Rettie AE, Goulart DA. Interaction of amiodarone with racemic warfarin and its separated enantiomorphs in humans. Clin Pharmacol Ther 1987;42: 290-4.
31. Neyroz P, Bonati M. In vitro amiodarone protein binding and its interaction with warfarin. Experientia 1985;41:361-3.
32. Serlin MJ, Breckenridge AM. Drug interactions with warfarin. Drugs 1983;25:610-20.
33. Sketris IS, Wright MR, West ML. Possible role of the intestinal P-450 enzyme system in a cyclosporine-clarithromycin interaction. Pharmacotherapy 1996;16:301-5.
34. Gourley DR, Ueda CT. Pharmaceutics and pharmacy practice. In: Banker GS, Chalmers RK, eds. Patient factors that influence dosage form selection. Philadelphia: JB Lippincott, 1982:144-9.
35. Midoneck SR, Etingin OR. Clarithromycin-related toxic effects of digoxin. N Engl J Med 1995;333:1505.
36. Ford A, Smith LC, Baltch AL, Smith RP. Clarithromycin-induced digoxin toxicity in a patient with AIDS. Clin Infect Dis 1995;21:1051-2.
37. Nawarskas JJ, McCarthy DM, Spinier SA. Digoxin toxicity secondary to clarithromycin therapy. Ann Pharmacother 1997;31:864-6.
38. Brown BA, Wallace RJ, Griffith DE, Warden R. Clarithromycin-associated digoxin toxicity in the elderly. Clin Infect Dis 1997;24:92-3.